Kura Oncology, Inc.
KURA
$7.58
-$0.07-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.28M | 67.99M | 53.88M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.28M | 67.99M | 53.88M | -- | -- |
| Cost of Revenue | 274.11M | 251.05M | 231.34M | 76.00M | 76.00M |
| Gross Profit | -190.83M | -183.06M | -177.46M | -76.00M | -76.00M |
| SG&A Expenses | 90.25M | 81.76M | 77.11M | 67.27M | 62.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 302.98M | 271.43M | 247.08M | 217.50M | 200.09M |
| Operating Income | -219.71M | -203.44M | -193.20M | -217.50M | -200.09M |
| Income Before Tax | -194.93M | -179.64M | -171.97M | -197.55M | -181.75M |
| Income Tax Expenses | 2.24M | 2.24M | 2.02M | -- | -- |
| Earnings from Continuing Operations | -197.17 | -181.89 | -173.98 | -197.55 | -181.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.17M | -181.89M | -173.98M | -197.55M | -181.75M |
| EBIT | -219.71M | -203.44M | -193.20M | -217.50M | -200.09M |
| EBITDA | -218.83M | -202.59M | -192.35M | -216.64M | -199.23M |
| EPS Basic | -2.26 | -2.09 | -2.02 | -2.36 | -2.23 |
| Normalized Basic EPS | -1.49 | -1.38 | -1.34 | -1.55 | -1.47 |
| EPS Diluted | -2.26 | -2.09 | -2.02 | -2.36 | -2.23 |
| Normalized Diluted EPS | -1.49 | -1.38 | -1.34 | -1.55 | -1.47 |
| Average Basic Shares Outstanding | 349.09M | 348.14M | 344.63M | 334.83M | 325.12M |
| Average Diluted Shares Outstanding | 349.09M | 348.14M | 344.63M | 334.83M | 325.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |